Talk to your doctor about how HAEGARDA can be an effective and safe therapy for children

• The safety and effectiveness of HAEGARDA were evaluated in subgroups within both short- and long-term clinical trials. These subgroups, part of the larger studies, consisted of nine patients, 8 to <17 years of age. Results within this age group were consistent with overall study results

Before taking any HAE therapies, consult with your doctor if you are pregnant or considering becoming pregnant

• In a long-term study, four pregnant women with type I HAE and ranging in age from 19 to 32 years received HAEGARDA. These women received 40–60 IU/kg per subcutaneous administration for 4–8 weeks (9–15 doses) during the first trimester. These women reported no complications during delivery, and all women delivered healthy babies^||

It is not known if HAEGARDA can harm your unborn baby. It is not known if HAEGARDA passes into your milk and if it can harm your baby

^||Due to study protocols, these patients were not eligible to continue the trial beyond the first trimester.